Skip to main content

  • GLP-1 Agonists May Reduce Adverse CV Event Risk Regardless of SGLT2 Inhibitor Use in Patients with T2D, CVD: Post Hoc Analysis

    In patients with type 2 diabetes (T2D) and cardiovascular disease, treatment with a GLP-1 receptor agonist (GLP-1 RA) reduces the risk of adverse cardiovascular events independently of background sodium-glucose cotransporter-2 (SGLT2) inhibitor use, according to researchers.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details